Lam Hoai Xuân-Lan, De Maertelaer Viviane, Simonart Thierry
Department of Dermatology, St Pierre - Brugmann - Hôpital Universitaire Des Enfants Reine Fabiola (HUDERF) University Hospitals, Université Libre de Bruxelles, Belgium.
Department of Biostatistics, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, Brussels, Belgium.
JAAD Int. 2021 Jan 13;2:109-115. doi: 10.1016/j.jdin.2020.12.006. eCollection 2021 Mar.
Real-life data on topical treatments in daily practice in patients with moderate acne are poorly characterized.
To investigate the drug survival of topical treatments administered to patients with moderate acne in a daily practice.
Survival analysis was performed on subjects (Belgian university hospital and private practice outpatient dermatology patients) with moderate acne who received topical therapies according to the current published guidelines.
A total of 1160 treatment series (1029 patients) were included, including benzoyl peroxide (BPO, n = 93), azelaic acid (n = 246), adapalene (n = 254), a fixed combination of adapalene 0.1% and BPO 2.5% (A/BPO, n = 264), and a fixed combination of clindamycin 1.2% and tretinoin 0.025% gel (Clin-RA, n = 303). The calculated overall median treatment duration of all drugs was 2 months. The probability of treatment discontinuation after only 3 months was 50%. Overall, the drugs were discontinued for the following reasons: controlled acne (9%), side effects (9%), ineffectiveness (52%), combination of side effects and ineffectiveness (3%), and other reasons (1%). Overall, 27% patients were lost to follow-up.
The post hoc study design and generalizability limit interpretation of the data.
Overall, the median treatment duration of topical anti-acne therapies was short (2 months). The main reason for discontinuation was ineffectiveness.
中度痤疮患者日常实践中局部治疗的实际数据特征不明确。
调查日常实践中给予中度痤疮患者的局部治疗药物的留存率。
对根据当前已发表指南接受局部治疗的中度痤疮患者（比利时大学医院和私人诊所皮肤科门诊患者）进行生存分析。
共纳入1160个治疗序列（1029例患者），包括过氧化苯甲酰（BPO，n = 93）、壬二酸（n = 246）、阿达帕林（n = 254）、0.1%阿达帕林与2.5%BPO的固定组合（A/BPO，n = 264）以及1.2%克林霉素与0.025%维甲酸凝胶的固定组合（Clin-RA，n = 303）。所有药物计算得出的总体中位治疗持续时间为2个月。仅3个月后治疗中断的概率为50%。总体而言，药物中断的原因如下：痤疮得到控制（9%）、副作用（9%）、无效（52%）、副作用与无效合并（3%）以及其他原因（1%）。总体而言，27%的患者失访。
事后研究设计以及数据的可推广性限制了对数据的解读。
总体而言，局部抗痤疮治疗的中位治疗持续时间较短（2个月）。中断治疗的主要原因是无效。
